Patents by Inventor Jill Walker

Jill Walker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-PD-L1 ANTIBODY TREATMENT OF BLADDER CANCER
    Publication number: 20220332828
    Abstract: Provided are methods of treating bladder cancer (e.g., urothelial carcinoma, UC) in a subject having bladder cancer, e.g., UC, with an effective dose regimen of an anti-PD-L1 antibody, e.g., durvalumab, or an antigen binding fragment thereof. Also provided are methods in which an anti-PD-L1 antibody is used in combination with another immunotherapeutic agent, e.g., tremelimumab to treat a bladder cancer, e.g., UC, in a subject having bladder cancer. In some cases, the subject undergoing treatment is identified as having a bladder cancer or tumor that is PD-L1-low/neg, or PD-L1-high. Methods are also provided in which anti-PD-L1 antibody treatment of bladder cancer is used following a standard of care or first-line therapy in subjects who have progressed following such therapies or who have relapsed after a prior treatment regimen.
    Type: Application
    Filed: April 14, 2022
    Publication date: October 20, 2022
    Inventors: JOHN KURLAND, JOHN ANDREW BLAKE-HASKINS, MAGDALENA ZAJAC, MARLON REBELATTO, ASHOK GUPTA, TONY HO, JILL WALKER, XIAOPING JIN, SHANNON MORRIS, ROBERT IANNONE, LI SHI, MOHAMMED DAR, YONG BEN
  • ANTI-PD-L1 ANTIBODY TREATMENT OF BLADDER CANCER
    Publication number: 20190359715
    Abstract: Provided are methods of treating bladder cancer (e.g., urothelial carcinoma, UC) in a subject having bladder cancer, e.g., UC, with an effective dose regimen of an anti-PD-L1 antibody, e.g., durvalumab, or an antigen binding fragment thereof. Also provided are methods in which an anti-PD-L1 antibody is used in combination with another immunotherapeutic agent, e.g., tremelimumab to treat a bladder cancer, e.g., UC, in a subject having bladder cancer. In some cases, the subject undergoing treatment is identified as having a bladder cancer or tumor that is PD-L1-low/neg, or PD-L1-high. Methods are also provided in which anti-PD-L1 antibody treatment of bladder cancer is used following a standard of care or first-line therapy in subjects who have progressed following such therapies or who have relapsed after a prior treatment regimen.
    Type: Application
    Filed: February 16, 2018
    Publication date: November 28, 2019
    Inventors: JOHN KURLAND, JOHN ANDREW BLAKE-HASKINS, MAGDALENA ZAJAC, MARLON REBELATTO, ASHOK GUPTA, TONY HO, JILL WALKER, XIAOPING JIN, SHANNON MORRIS, ROBERT IANNONE, LI SHI, MOHAMMED DAR, YONG BEN
  • Therapeutic methods
    Patent number: 10238678
    Abstract: The present invention features a method for the treatment of Hepatitis C in a human in need thereof comprising administering a compound of Formulas (II) or (IIB) described herein or a pharmaceutically acceptable salt thereof in combination with one or more alternative Hepatitis C therapeutic agents.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: March 26, 2019
    Assignee: GlaxoSmithKline LLC
    Inventors: Jill Walker, Christian Voitenleitner
  • Therapeutic Methods
    Publication number: 20150320777
    Abstract: The present invention features a method for the treatment of Hepatitis C in a human in need thereof comprising administering a compound of Formulas (II) or (IIB) described herein or a pharmaceutically acceptable salt thereof in combination with one or more alternative Hepatitis C therapeutic agents.
    Type: Application
    Filed: July 20, 2015
    Publication date: November 12, 2015
    Inventors: Jill Walker, Christian Voitenleitner
  • Therapeutic methods
    Patent number: 9119868
    Abstract: The present invention features a method for the treatment of Hepatitis C in a human in need thereof comprising administering a compound of Formulas (II) or (IIB) described herein or a pharmaceutically acceptable salt thereof in combination with one or more alternative Hepatitis C therapeutic agents.
    Type: Grant
    Filed: August 17, 2012
    Date of Patent: September 1, 2015
    Assignee: GlaxoSmithKline LLC
    Inventors: Jill Walker, Christian Voitenleitner
  • Combination Treatments For Hepatitis C
    Publication number: 20140234253
    Abstract: The present invention features methods and pharmaceutical compositions for the treatment of Hepatitis C in a human in need thereof comprising administering a compound of Formula (I), (II), (III), (IV), (V), or (VI) described herein or a pharmaceutically acceptable salt thereof in combination with one or more additional Hepatitis C therapeutic agents.
    Type: Application
    Filed: August 24, 2012
    Publication date: August 21, 2014
    Applicant: GlaxoSmithKline LLC
    Inventors: Jill Walker, Christian Voitenleitner
  • Therapeutic Methods
    Publication number: 20140212384
    Abstract: The present invention features a method for the treatment of Hepatitis C in a human in need thereof comprising administering a compound of Formulas (II) or (IIB) described herein or a pharmaceutically acceptable salt thereof in combination with one or more alternative Hepatitis C therapeutic agents.
    Type: Application
    Filed: August 17, 2012
    Publication date: July 31, 2014
    Inventors: Jill Walker, Christian Voitenleitner